Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment
Open Access
- 1 January 2012
- journal article
- review article
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 10 (1), 32
- https://doi.org/10.1186/1477-7827-10-32
Abstract
Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of controlled ovarian stimulation (COS) as part of assisted reproductive technologies (ART). While the safety and efficacy of ART is well established, physicians should always be aware of the risk of OHSS in patients undergoing COS, as it can be fatal. This article will briefly present the pathophysiology of OHSS, including the key role of vascular endothelial growth factor (VEGF), to provide the foundation for an overview of current techniques for the prevention of OHSS. Risk factors and predictive factors for OHSS will be presented, as recognizing these risk factors and individualizing the COS protocol appropriately is the key to the primary prevention of OHSS, as the benefits and risks of each COS strategy vary among individuals. Individualized COS (iCOS) could effectively eradicate OHSS, and the identification of hormonal, functional and genetic markers of ovarian response will facilitate iCOS. However, if iCOS is not properly applied, various preventive measures can be instituted once COS has begun, including cancelling the cycle, coasting, individualizing the human chorionic gonadotropin trigger dose or using a gonadotropin-releasing hormone (GnRH) agonist (for those using a GnRH antagonist protocol), the use of intravenous fluids at the time of oocyte retrieval, and cryopreserving/vitrifying all embryos for subsequent transfer in an unstimulated cycle. Some of these techniques have been widely adopted, despite the scarcity of data from randomized clinical trials to support their use.Keywords
This publication has 78 references indexed in Scilit:
- Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trialJournal of Assisted Reproduction and Genetics, 2012
- Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicityHuman Reproduction, 2011
- Vitrified-warmed blastocyst transfer cycles yield higher pregnancy and implantation rates compared with fresh blastocyst transfer cycles—time for a new embryo transfer strategy?Fertility and Sterility, 2011
- Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patientsReproductive Biology and Endocrinology, 2011
- Ovarian hyperstimulation syndrome: pathophysiology and preventionJournal of Assisted Reproduction and Genetics, 2010
- Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “Tap early and often” versus hospitalizationFertility and Sterility, 2010
- The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndromeFertility and Sterility, 2009
- A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocolHuman Reproduction, 2009
- Ovarian hyperstimulation syndrome and prophylactic human embryo cryopreservation: analysis of reproductive outcome following thawed embryo transferJournal of Ovarian Research, 2008
- Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilizationReproductive Biology and Endocrinology, 2007